Alpha 2.0

» Articles » PMID: 32346443

Effects of Nanoparticle-mediated Delivery of Pitavastatin on Atherosclerotic Plaques in ApoE-knockout Mice and THP-1-derived Macrophages

Overview

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2020 Apr 30

PMID 32346443

Citations 3

Authors

Authors

Yujiao Sun

Ling Chen

Shijie Zhao

Liye Shi

Hua Li

Wen Tian

Guoxian Qi

Affiliations

Affiliations

Soon will be listed here.

Abstract

The treatment of atherosclerosis remains complex. Pitavastatin serves an important role in the prevention and treatment of atherosclerosis. The present study aimed to investigate the effects of nanoparticle (NP)-mediated delivery of pitavastatin into atherosclerotic plaques as a novel treatment method for atherosclerosis. The results of the present study demonstrated that pitavastatin-NP was more effective in attenuating the size of atherosclerotic plaques and enhancing the stability of plaques compared with pitavastatin alone. In an apolipoprotein E (ApoE)-knockout mouse model of atherosclerosis, a single intravenous injection of fluorescein isothiocyanate-NP resulted in the delivery of NP into atherosclerotic plaques for up to 7 days post-injection. In ApoE-knockout mice and THP-1-derived macrophages, pitavastatin-NP attenuated the development of atherosclerosis, which was associated with regulating lipid metabolism, and inhibited the secretion of inflammatory markers compared with pitavastatin alone. Additionally, the treatment advantages of pitavastatin-NP were independent of lipid lowering. The results demonstrated that pitavastatin-NP administration was more effective in attenuating the development of atherosclerotic plaques compared with systemic administration of pitavastatin.

Citing Articles

Research progress on the therapeutic effects of nanoparticles loaded with drugs against atherosclerosis.

Shi T, Liu K, Peng Y, Dai W, Du D, Li X Cardiovasc Drugs Ther. 2023; 38(5):977-997.

PMID: 37178241 DOI: 10.1007/s10557-023-07461-0.

Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apoe Mice.

Katsuki S, Koga J, Matoba T, Umezu R, Nakashiro S, Nakano K J Atheroscler Thromb. 2021; 29(1):111-125.

PMID: 33455994 PMC: 8737070. DOI: 10.5551/jat.54379.

Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Chen J, Zhang X, Millican R, Sherwood J, Martin S, Jo H Adv Drug Deliv Rev. 2021; 170:142-199.

PMID: 33428994 PMC: 7981266. DOI: 10.1016/j.addr.2021.01.005.

References

1.

Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S . A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model. PLoS One. 2015; 10(7):e0132451. PMC: 4500569. DOI: 10.1371/journal.pone.0132451. View

2.

Starr T, Bauler T, Malik-Kale P, Steele-Mortimer O . The phorbol 12-myristate-13-acetate differentiation protocol is critical to the interaction of THP-1 macrophages with Salmonella Typhimurium. PLoS One. 2018; 13(3):e0193601. PMC: 5851575. DOI: 10.1371/journal.pone.0193601. View

3.

Matoba T, Egashira K . Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014; 55(4):281-6. DOI: 10.1536/ihj.14-150. View

4.

Leuschner F, Nahrendorf M . Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ Res. 2011; 108(5):593-606. PMC: 3397211. DOI: 10.1161/CIRCRESAHA.110.232678. View

5.

Banfi C, Baetta R, Gianazza E, Tremoli E . Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins. Drug Discov Today. 2017; 22(6):848-869. DOI: 10.1016/j.drudis.2017.03.001. View

6.

Daley J, Thomay A, Connolly M, Reichner J, Albina J . Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol. 2007; 83(1):64-70. DOI: 10.1189/jlb.0407247. View

7.

McLaren J, Michael D, Ashlin T, Ramji D . Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011; 50(4):331-47. DOI: 10.1016/j.plipres.2011.04.002. View

8.

Matoba T, Koga J, Nakano K, Egashira K, Tsutsui H . Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease. J Cardiol. 2017; 70(3):206-211. DOI: 10.1016/j.jjcc.2017.03.005. View

9.

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

10.

Oda S, Nagahama R, Nakano K, Matoba T, Kubo M, Sunagawa K . Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J Vasc Surg. 2010; 52(2):412-20. DOI: 10.1016/j.jvs.2010.03.020. View

11.

Helin-Salmivaara A, Lavikainen P, Korhonen M, Halava H, Martikainen J, Saastamoinen L . Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care. 2010; 16(2):116-22. View

12.

Kawashiri M, Yamagishi M, Sakamoto T, Takayama T, Hiro T, Daida H . Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in.... Cardiovasc Ther. 2013; 31(6):335-43. DOI: 10.1111/1755-5922.12027. View

13.

Bhavane R, Badea C, Ghaghada K, Clark D, Vela D, Moturu A . Dual-energy computed tomography imaging of atherosclerotic plaques in a mouse model using a liposomal-iodine nanoparticle contrast agent. Circ Cardiovasc Imaging. 2013; 6(2):285-94. PMC: 3760185. DOI: 10.1161/CIRCIMAGING.112.000119. View

14.

Weissleder R, Nahrendorf M, Pittet M . Imaging macrophages with nanoparticles. Nat Mater. 2014; 13(2):125-38. DOI: 10.1038/nmat3780. View

15.

Leuschner F, Dutta P, Gorbatov R, Novobrantseva T, Donahoe J, Courties G . Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011; 29(11):1005-10. PMC: 3212614. DOI: 10.1038/nbt.1989. View

16.

Leon C, Hill J, Wasan K . Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm Res. 2005; 22(10):1578-88. DOI: 10.1007/s11095-005-6306-0. View

17.

Berman J, Farkouh M, Rosenson R . Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs. 2013; 18(2):193-205. DOI: 10.1517/14728214.2013.801453. View

18.

Tsukie N, Nakano K, Matoba T, Masuda S, Iwata E, Miyagawa M . Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J Atheroscler Thromb. 2012; 20(1):32-45. DOI: 10.5551/jat.13862. View

19.

Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S . Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv. 2009; 2(4):277-83. DOI: 10.1016/j.jcin.2008.08.023. View

20.

Zhang W, Yancey P, Ru Su Y, Babaev V, Zhang Y, Fazio S . Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 2003; 108(18):2258-63. DOI: 10.1161/01.CIR.0000093189.97429.9D. View